Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

NCT03935568 is registered in ClinicalTrials.gov with Samus Therapeutics, Inc. as lead sponsor.

NCT NCT03935568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03935568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects
Lead sponsor
Samus Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
June 24, 2019
Completion date
December 23, 2019
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease